BIOSYSEN (01355) has received valid acceptance for the share offer at approximately 57.09%.

BIOSYSEN (01355) announced that as of the record date, (i) the number of rights shares offered under the rights issue is 597 million shares (the "offered shares"); and (ii) there are no ineligible shareholders, and the number of rights shares not subscribed for by ineligible shareholders is zero. The Board of Directors announced that on August 18, 2026 (Tuesday) at 4:00 PM (i.e., the final acceptance deadline), a total of 15 valid acceptances were received for a total of 341 million rights shares, accounting for approximately 57.09% of the total offered shares. As a result, the subscription for the rights issue was insufficient, with 256 million rights shares unsubscribed, accounting for approximately 42.91% of the total offered shares, and those shares will be subject to the compensation arrangement. The Company will arrange to sell the 256 million unsubscribed rights shares through independent placees in accordance with Rule 7.21(1)(b) of the Listing Rules, with the proceeds belonging to shareholders who have received the offer in the form of rights shares. On June 24, 2026 (after trading hours), the Company entered into a placing agreement with the placing agent regarding the placement of the unsubscribed rights shares on a best effort basis to independent placees. Under the placing agreement, the Company appoints the placing agent to place the unsubscribed rights shares to independent placees on a best effort basis during the placing period, and any premium (net proceeds) exceeding (i) the subscription price for those rights shares; and (ii) the placing agent's fees (including any other related costs and expenses) will be paid to the relevant non-responding shareholders. The placing agent will facilitate subscribers to purchase all (or as many as possible) of those unsubscribed rights shares at a price not lower than the subscription price by 4:00 PM on September 2, 2026 (Wednesday) on a best effort basis. The Company will not issue any unsubscribed rights shares that are not placed under the compensation arrangement, and the scale of the rights issue will be correspondingly reduced. Any net proceeds (if any) will be paid to non-responding shareholders on a pro-rata basis (rounded down to the nearest cent), as follows: A. Payments to relevant eligible shareholders who have not made a valid application for the unpaid rights shares based on the number of shares they hold for which no valid application was made for the unpaid rights shares; and B. Payments to relevant ineligible shareholders based on their shareholding in the Company on the record date. In respect of any net proceeds, if any non-responding shareholder is entitled to receive an amount of HKD 100 or more based on the above basis, such amount will be paid only in HKD to the relevant non-responding shareholder, while any individual amount less than HKD 100 will be retained by the Company.